Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02095834 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

DRUG: Bendamustine Hydrochloride
DRUG: Carfilzomib
DRUG: Dexamethasone
OTHER: Laboratory Biomarker Analysis

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]